Our supplements are made with no hidden ingredients and focus on optimal bioavailability through advanced liposomal delivery systems
Retatrutide: Still undergoing clinical trials, Retatrutide shows promising potential for both glucose control and weight reduction
The 2025 safety assessment of allulose by Food Standards Australia New Zealand concluded that, based on "the history of safe use of D-allulose internationally, the weight-of-evidence suggests adverse microbiological effects are unlikely." As noted by Daniel et al
GLP-1 medications are not typically considered short-term interventions - weight regain after stopping is documented in clinical literature
Differential proteomic analysis of highly purified placental cytotrophoblasts in pre-eclampsia demonstrates a state of increased oxidative stress and reduced cytotrophoblast antioxidant defense
A review of large clinical trials of GLP-1RAs identified that the most common injection site reactions were rash, erythema, and pruritus